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Sorafenib is the unique accepted molecular targeted drug for the treatment of
patients in advanced stage of hepatocellular carcinoma. The current study evaluated
cell signaling regulation of endoplasmic reticulum (ER) stress, c‐Jun‐N‐terminal kinase
(JNK), Akt, and 5′AMP‐activated protein kinase (AMPK) leading to autophagy and
apoptosis induced by sorafenib. Sorafenib induced early (3–12 hr) ER stress
characterized by an increase of Ser51P‐eIF2α/eIF2α, C/EBP homologous protein
(CHOP), IRE1α, and sXBP1, but a decrease of activating transcription factor 6
expression, overall temporally associated with the increase of Thr183,Tyr185P-JNK1/2/
JNK1/2, Thr172P‐AMPKα, Ser413P‐Foxo3a, Thr308P‐AKt/AKt and Thr32P‐Foxo3a/Foxo3a
ratios, and reduction of Ser2481P‐mammalian target of rapamycin (mTOR)/mTOR and
protein translation. This pattern was related to a transient increase of tBid, BimEL,
Beclin‐1, Bcl‐xL, Bcl‐2, autophagy markers, and reduction of myeloid cell leukemia‐1
(Mcl-1) expression. The progressive increase of CHOP expression, and reduction of
Thr308P‐AKt/AKt and Ser473P‐AKt/AKt ratios were associated with the reduction of
autophagic flux and an additional upregulation of BimEL expression and caspase‐3
activity (24 hr). Small interfering‐RNA (si‐RNA) assays showed that Bim, but not Bak
and Bax, was involved in the induction of caspase‐3 in sorafenib‐treated HepG2 cells.
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Sorafenib increased autophagic and apoptotic markers in tumor‐derived xenograft
model. In conclusion, the early sorafenib‐induced ER stress and regulation of JNK and
AMPK‐dependent signaling were related to the induction of survival autophagic
process. The sustained drug treatment induced a progressive increase of ER stress
and PERK‐CHOP‐dependent rise of BimEL, which was associated with the shift from
autophagy to apoptosis. The kinetic of BimEL expression profile might also be related
to the tight balance between AKt‐ and AMPK‐related signaling leading to Foxo3a‐
dependent BIMEL upregulation.
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1 | INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common type of liver
cancer and the second most frequent cause of cancer‐related death
worldwide (Llovet et al., 2016; Torre et al., 2015). HCC develops
within a cirrhotic liver in 80%–90% of cases that influences
therapeutic decisions (Fattovich, Stroffolini, Zagni, & Donato, 2004;
Sanyal, Yoon, & Lencioni, 2010). The difficulty in forming an early
diagnosis, at the first stage of the disease, contributes to the poor
response of patients to current clinical treatments. Currently, only
one‐third of newly diagnosed patients with HCC are an at early stage
(0 or A), according to the Barcelona Clinic Liver Cancer (BCLC)
staging system, and are eligible for potential curative therapies such
as local ablation, resection, or orthotopic liver transplantation with a
5‐year survival rate of 50%–80% (Bruix, Reig, & Sherman, 2016). The
recommended first‐line treatment for patients with locally advanced/
metastatic disease (BLCL C) is sorafenib with a mean overall survival
of 11 months (Cheng et al., 2009; Llovet et al., 2008).
Sorafenib inhibits tyrosine kinase receptors such as vascular
endothelial growth factor receptor (VEGFR) 2, VEGFR 3, platelet‐
derived growth factor receptor‐β (PDGFR‐β), Flt3 and c‐Kit, as well as
molecular components of the Raf/MEK/extracellular signal‐regulated
kinase (ERK) signaling pathway (Cervello et al., 2012). Different studies
have suggested that the increased susceptibility to cell death by
sorafenib is associated with down‐regulation of cell survival pathways in
hepatoma cells (Prieto‐Dominguez et al., 2016). In particular, Chen et al.
(2010) showed that sorafenib enhanced TRAIL‐induced cell death
through SH2 domain‐containing tyrosine phosphatase (SHP‐1)‐depen-
dent reduction of signal transducers and activators of transcription
type 3 (STAT3) phosphorylation (Tyr705STAT3) and related proteins
members myeloid cell leukemia‐1 (Mcl‐1), survivin, and cyclin D1 in
hepatoma cells. Sorafenib‐induced cell death is also related to
upregulation of the proapoptotic “BH3‐domain only” PUMA and BIM,
as well as a decrease of Mcl‐1 and survivin (Fernando et al., 2012). It has
also been shown that c‐Jun‐N‐terminal kinase (JNK)‐dependent
GADD45β (Ou et al., 2010) and PUMA (Fernando et al., 2012)
expressions are also involved in the proapoptotic properties of
sorafenib in HCC cells. Shimizu et al. (2012) showed that sorafenib
enhanced autophagy, pharmacological inhibition due to which increased
apoptosis and decreased cell viability in sorafenib‐treated Huh7, HLF,
and PLC/PRF/5 cells. However, other studies did not find a relationship
between autophagy induction and resistance to treatment in sorafenib‐
treated HCC cells (Fischer, Wang, Vlada, Kim, & Behrns, 2014). The
current study showed that the induction of autophagy in sorafenib‐
treated HepG2 cells is related to IRE‐1 and eIF2α‐dependent ER stress,
JNK and 5′AMP‐activated protein kinase (AMPK)‐dependent signaling.
The shift from autophagy to apoptosis is related to a decline of Beclin‐1,
Bcl‐2, Mcl‐1, Bcl‐xL, Bcl‐2, and tBid and the increase of proapoptotic
BimEL, Bak, and Bax.
2 | MATERIAL AND METHODS
2.1 | Chemical and reagents
Sorafenib (Ref FS10808; Carbosynth Limited, Berkshire, UK) was
dissolved in dimethyl sulfoxide as stock solution (100mM).
3‐MethylAdenine (3MA; Ref M9281), chloroquine (CQ; Ref C6628),
SP600125 (Ref S5567), and dorsomorphin (Ref P5499) were
obtained from Sigma‐Aldrich (Sant Louis, MO).
2.2 | Primary human hepatocytes, cell lines, and
culture conditions
Human hepatocytes were prepared from liver biopsies obtained from
three patients (two females and one male, aged 66±3.0 years) submitted
to surgical resection for liver tumors after obtaining the patients’ written
consent. Hepatocytes isolation was based on a two‐step collagenase
procedure (Pichard et al., 2006). HepG2 and Hep3B cell lines were
obtained from the American Type Culture Collection (LGC Standards, S.L.
U., Barcelona, Spain). Huh7 cell line was purchased from Apath, LLC
(Brooklyn, NY). Cell lines were selected according to their p53 content:
HepG2 (WT p53 expression), Huh7 (p53 mutated isoform, codon 220),
and Hep3b (nonsense p53 mutation). All lines were negative for
mycoplasma contamination. The cells were cultured in minimum essential
medium (MEM) with Earle’s salts with L‐glutamine (Ref E15–825, PAA)
with 10% fetal bovine serum (FBS; F7524, Sigma‐Aldrich, Lot No:
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022M3395, endotoxin < 0.2 EU/ml), sodium pyruvate (1mM; Ref S11‐
003, PAA), nonessential amino acids (Ref M11‐003, PAA),
penicillin‐streptomycin solution (100U/ml–100 μg/ml; P11‐010, PAA),
at 37°C in a humidified incubator with 5% CO2. The cells were cultured
at a cell density of 100,000 cells/cm2, treatment added 24 after plating,
and lysates were obtained at different time points after treatments.
Sorafenib was administrated at different concentrations (1 nM–100 μM).
Additional experimental interventions, such as 3MA (5 µM) and CQ (50
µM), were preadministered (2 hr), and dorsomorphin (5 µM) was
coadministered with sorafenib. The Biobank of the Institution approved
the use of primary biopsies of patients for the present research (Ref. no
33140031, April 1, 2014).
2.3 | Effect of sorafenib administration on
tumor growth in a xenograft mouse model
Sixty male Hsd:Athymic Nude‐Foxn1nu mice (Harlan Labora-
tories, Barcelona, Spain), aged 4 weeks (weighing 18–22 g), were
randomly distributed in three groups according to the subcuta-
neous implantation of HepG2, Hep3b, and Huh7. Cells (10 × 106)
were diluted in matrigel (Ref 356231, Lot 36821, Becton‐
Dickinson, NJ) and administered subcutaneously into the right
flank of the mice. Each experimental group was subdivided
into the group receiving sorafenib (200 mg/kg) and the group
receiving a solvent, which was constituted by ethanol:Koliphor EL
(C5135, Sigma‐Aldrich):0.9% NaCl (1:1:6). Sorafenib or solvent
was administered daily by oral gavage when the tumor diameter
grew to 5 mm (11 days) and ended at the sacrifice of animals
when tumor diameter was 15 mm (24 days). The tumor volume
was calculated using the formula: V = [(length) × (width) ×
(depth) × π]/6. All animal care and experimentation conformed
to the Guide for the Care and Use of Laboratory Animals
published by the National Academy of Sciences. The Ethical
Committee of the Institution approved the in vivo experiments
(Ref. no CEP2104 PI/016, January 30, 2014).
2.4 | Immunohistochemistry
Tumor tissue sections (5 µm) were obtained to analyze the expression of
α‐smooth muscle actin (α‐sma), Ki67, CD31, and CD34 by immunohis-
tochemistry. Sections were deparaffinized, hydrated through graded
ethanol steps, briefly rinsed in water, and blocked at room temperature
using TBSA‐BSAT (10mM Tris, 0.9% NaCl, 0.02% sodium azide, 2%
bovine serum albumin and 0.1% Triton‐X100). Slices were incubated
overnight at room temperature with primary antibodies against 1:250 α‐
sma (ab5694; Abcam, Cambridge, UK), 1:500 (Ki67, IR626; DAKO,
Glostrup, Denmark), 1:50 CD31 (ab28364; Abcam), and 1:200 CD34
(ab64480; Abcam), followed by incubation with the corresponding
secondary antibodies, either Alexa 488 anti‐rabbit IgG (A11008;
Invitrogen, Carlsbad, CA, Spain) or Alexa 488 anti‐mouse IgG (A11001;
Invitrogen), for 5 hr diluted in TBSA‐BSAT (1:500). Nuclear staining was
performed using DRAQ‐5th (red fluorescent cell‐permeable DNA probe;
Biostatus Limited, Loughborough, UK). Immunofluorescence analysis was
performed using an Olympus BX61 microscope (Tokyo, Japan). Fluores-
cence quantification was performed using Leica Application Suite
Advanced Fluorescence software and ImageJ software (Wetzlar,
Germany).
2.5 | Ultrastructural analysis by transmission
electronic microscopy
Treated and control cells were isolated and prefixed in 1.5% formalde-
hyde in 1% cacodylate buffer, pH 7.4, for 2 hr at 4°C. After three washes
in cacodylate buffer, the extracts were fixed in 1% osmium tetroxide for
60min at 0–4°C. The samples were dehydrated in graded ethanol and
embedded in Epon resin. After overnight incubation at 65°C, ultrathin
sections (70 nm) were cut with a diamond knife using an Ultracut S
ultramicrotome and placed on 200‐mesh copper grids. All sections were
stained with uranyl acetate, counterstained with lead citrate, and viewed
using a Carl Zeiss (Oberkochen, Germany) EM10C electron microscope
at 4,646×, 10,000×, and 46,460× magnifications in the Biomedical
Research Center at the University of Granada’s Health Technology Park.
2.6 | Measurement of cell death
Caspase‐3‐associated activities were determined using Caspase‐
Glo® 3 Assay Systems (G8091; Promega, Madison). Cells were
treated with Caspase‐Glo® 3 in an “add‐mix‐measure” format
resulting in cell lysis, caspase‐3‐dependent cleavage of the substrate
and generation of a “glow‐type” luminescent signal. The signal
generated was proportional to the amount of caspase activity. The
values are extrapolated into a calibration curve included in the assay.
Cell death in tissue sections was determined using the DeadEnd™
fluorometric terminal deoxynucleotidyl transferase mediated dUTP
nick‐end labeling (TUNEL) System (G3250, Promega) that measures
the fragmented DNA of apoptotic cells by catalytically incorporating
fluorescein‐12‐dUTP at 3′‐OH DNA ends using the enzyme terminal
deoxynucleotidyl transferase (TdT), which forms a polymeric tail
using the principle of the TUNEL assay. The fluorescein‐12‐dUTP‐
labeled DNA was visualized using an Olympus BX61 microscope.
Fluorescence quantification was performed using Leica Application
Suite Advanced Fluorescence software and the ImageJ software.
2.7 | Cell proliferation
The measurement of bromodeoxyuridine (BrdU) incorporation
was used as marker of cell proliferation (Ref. 11647229001;
Roche Diagnostics, Indianapolis, IN). Cells were seeded in 96‐well
plates at low density (12,500 cells/cm2). Two hours before
sampling, 20 μl of BrdU (10 μM) was added to the cultures. DNA
was denaturalized with 200 μl FixDenat solution included in the
commercial assay for 30 min at room temperature. After removal,
the cells were incubated with 100 μl monoclonal anti‐BrdU
antibody HRP conjugated for 90 min at room temperature.
Afterwards, the cells were washed with PBS and incubated with
100 μl reveling solution including hydrogen peroxide, luminol and
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4‐iodophenol for 15 min at room temperature. Absorbance was
measured at 370 nm using an Infinite 200 PRO Microplate Reader
(TECAN, Männedorf, Switzerland).
2.8 | Assessment of protein expression of
ER stress, autophagy, and apoptosis markers
Cells or tumor tissues were treated with lysis solution including
50mM HEPES pH. 7.5, 5mM ethylenediaminetetraacetic acid (EDTA),
150mM NaCl, 1% NP‐40, a commercial proteases inhibitor cocktail
(P8340, Sigma‐Aldrich), 1mM phenylmethanesulfonyl fluoride (PMSF),
1mM NaF, and 1mM Na3VO4. Protein expression were determined by
SDS‐PAGE coupled to western‐blot analysis. Proteins (50–100 μg) were
separated by Any kD™ Criterion™ TGX Stain‐Free™ Protein Gel, 18 well,
30 µl (#5678124; BioRad, Hercules, CA) and transferred to polyvinyli-
dene difluoride (PVDF) membranes. The system uses stain‐free
technology, which is a method that appears to be more reliable as a
protein loading control than measurement of housekeeping proteins
(Colella et al., 2012). The membranes were incubated with the
corresponding commercial primary and secondary antibodies coupled
to horseradish peroxidase revealing protein content by Clarity™Western
ECL substrate (Ref 170‐5061; BioRad) and analyzed in a ChemiDoc™
Touch Imaging System. Antibodies for western‐blot, tBid (#2002), eIF2α
(#5324), inositol‐requiring enzyme 1α (IRE1α, #3294), p62 (#5114),
Ser51P‐eIF2α (#9721), Ser2481P‐mammalian target of rapamycin (mTOR)
(#2974), AMPK (#5832), Thr172P‐AMPK (#2525), Bcl‐xL (#27625), Bcl‐2
(#2872), Bax (#5023), Bak (#12105), Bim (#2933), FoxO3a (#2497),
Ser413P‐FoxO3a (#8174), Thr32P‐FoxO3a (#9464), and cleaved PARP
(#9542) were commercially obtained from Cell Signaling Technology
(Danvers, MA); activating transcription factor 6 (ATF6, ab122897) was
purchased from Abcam; LC3 (PM036) was purchased from MBL
International (Woburn, MA); Beclin‐1 (sc‐11427), GADD153/CHOP
(sc‐575) and AKt (sc‐1618) were obtained from Santa Cruz Biotechnol-
ogy Inc. (Texas); Thr308P‐AKt (SAB4504740), Ser473P‐AKt (SAB4300042),
JNK1/2 (SAB4200176), Thr183,Tyr185P-JNK1/2 (J4644) and Mcl‐1
(SAB4501843) were obtained from Sigma‐Aldrich. The corresponding
secondary antibodies anti‐rabbit (sc‐2004), anti‐mouse (sc‐2005) and
anti‐goat (sc‐2768) IgG‐HRP labled were purchased from Santa Cruz.
Densitometric analysis was performed using the software Image Lab 6.0
of BioRad.
2.9 | XBP1s/XBP1 mRNA expression ratio
by qRT‐PCR
RNA was isolated using TRIsure Reagent (BIO‐38033; Bioline Reagents
Ltd., London, UK), and submitted to retrotranscription (iScript™ cDNA
Synthesis Kit #1708891; BioRad) and amplification by real-time
quantitative reverse transcription polymerase chain reaction (RT‐qPCR)
(iTaq™ Universal SYBR® Green Supermix #1725142; BioRad). RT‐PCR
was performed in ViiA™ 7 Real‐Time PCR System (Applied Biosystems,
Thermo Fisher Scientific, Waltham, MA) with a QuantumStudio™ Real
Time PCR Software. Reactions were performed in 96‐well plates with an
optical sealing tape (Thermo Fisher Scientific) in 25 μl total volume
containing SyberGreen Mix and the corresponding cDNA. Histone 3
(H3B3) was used as internal control in parallel for each run. The
conditions for amplification were as follows: polymerase activation and a
DNA denaturation step of 95°C for 40 s; 30 cycles of amplification
composed of a denaturation step of 95°C for 20 s and annealing/
extension+plate read at the optimized temperature of each couple of
primers (54–60 °C) for 60 s; and a final melt curve analysis of
95°C 15 s, 60°C 60 s and 95°C 15 s. All primers were designed using
online Primer3 software Primer3input and purchased from Eurofins
(Eurofins Genomics):
Primer Sequence 5′‐3′ Tm, °C
XBP1s Fw CGG GTC TGC TGA GTC CGC AGC AG 69.6
XBP1 Fw GCA GGT GCA GGC CCA GTT GTC AC 67.8
XBP1s Rv CCC CAC TGA CAG AGA AAG GGA GG 66
XBP1 Rv CCC CAC TGA CAG AGA AAG GGA GG 66
2.10 | si‐RNA interference
HepG2 cells were seeded in 6‐well plates the day before transfection to
reach a confluency of 60% in 24hr. Transfection was conducted with the
siTran 1.0 Transfection Reagent (siTranTM si-RNA transfection; Origene,
Rockville, MD) according to recommendations of the manufacturer. The
si-RNA of IRE1α, pancreatic ER kinase (PKR)‐like ER kinase (PERK), and
ATF6 were synthesized by Origene. Their targeting sequences can be
accessed from the Origene webpage with the references SR301457
(IRE1α, NM_001433), SR306267 (PERK, NM_004836), and SR307883
(ATF6, NM_007348). A nontargeting si-RNA (SR30004, Trilencer‐27
Universal Scrambled Negative Control si-RNA Duplex) also purchased
from Origene was used as negative control. Sorafenib was added 48hr
after transfection.
si‐RNA for knock‐down Bax (L‐003308‐01‐0005), Bak (L‐003305‐
00‐0005), Bim (L‐004385‐00‐0005), FoxO3a (L‐003007‐00‐0005),
and scramble (D‐001810‐10‐05) were obtained from Dharmacon
(Lafayette, CO) and used in HepG2 cells cultured at 20,000 cells/cm2.
si‐RNA (25 nM) were mixed with the transfection reagent Dharma-
FECT1 (Ref T‐2001‐02) for 20min at room temperature and
transferred to culture medium without antibiotic/antimycotic solu-
tion and kept for 24 hr prior to treatment. Afterwards, transfected
cells were maintained until the end of the experiment following the
manufacturer’s recommendations.
2.11 | pDest‐LC3‐GFP‐mCherry transient
transfection and detection of punctuate LC3‐positive
structures
Expression of pH‐sensitive sensor constructed as a tandem fusion
of mCherry and GFP to LC3B (pDest‐LC3‐GFP‐mCherry) was used
to monitor autophagy in HepG2 cells (kindly provided by Dr. Terje
Johansen). The GFP tag is acid‐sensitive, whereas the mCherry tag
is acid‐insensitive. Yellow merge punctate structures indicate
autophagosomes which neutral pH allows both tags emit
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fluorescent light resulting in a yellow staining. Subsequent fusion
of autophagosomes with lysosomes results in red‐positive acidic
vacuoles, where the green fluorescence from GFP is lost.
HepG2 cells were seeded in 24‐well plates with coverslips
at 2 × 105 cells/ml, and 500 µl of antibiotic free medium per well.
After 24 hr, the cells were transiently transfected with pDest‐LC3‐
GFP‐mCherry construct with Lipofectamine 2000 (Ref 11668027;
Invitrogen), according to the manufacturer’s protocol (2 µl of
Lipofectamine and 3 µg of plasmid per well). The following day, the
cells were treated with Earle’s balanced salt solution (Sigma,
E2888) and CQ (50 µM) as negative and positive control,
respectively. Sorafenib was administered at 10 µM and 100 µM.
All these treatments lasted for 6, 12, or 24 hr. Once the treatments
were finished, the medium was recovered, and the cells were
washed with phosphate saline buffer (PBS1X). The cells were
immediately fixed by using a 4% (w/v) paraformaldehyde solution
in PBS1X for 30 min. Nuclei were stained with Hoechst 33342 and
coverslips were mounted in slides with Fluoromount G (Invitrogen,
00‐4958‐02). Fluorescence images were obtained with an inverted
microscope (IX‐51, Olympus) provided with a DP‐70 camera.
Image analyses were performed using IFDOTMETER (Rodriguez‐
Arribas et al., 2016) and ImageJ. The quantifications of the number
of mCherry positive, corresponding to red‐positive acidic autop-
hagolysosome vacuoles, and GFP+mCherry positive, correspond-
ing to yellow‐positive autophagosome, were both measured at
6, 12, and 24 hr.
2.12 | Assessment of protein translation
The protocol adapted for polysome preparation of HepG2 cells was the
one we routinely employ for yeast cells (Kressler, de la Cruz, Rojo, &
Linder, 1997). Briefly, HepG2 cells were grown to 80% confluency in
175 cm2 dishes as described above. Normally, two dishes were used per
condition assayed. Before harvesting the cells, 200 µg/ml cycloheximide
was added and incubated for 5min at 37°C. Each dish was then placed
on ice, the medium was collected, and the cultures washed twice with
PBS without Ca2+ and Mg2+ containing 200 µg/ml cycloheximide. Then,
600 µl of lysis buffer (10mM Tris–HCl, pH7.4, 150mM NaCl, 10mM
MgCl2, 200 µg/ml cycloheximide, 200 µg/ml heparin, 2mM dithiothrei-
tol (DTT), 0.5% NP40) was added to one dish, cells were scraped, and
transferred to the second dish. After scraping the cells corresponding to
the second dish, the whole juice was transferred to a 1.5ml‐Eppendorf
tube. The tubes were incubated at 4°C with gentle end‐over‐end
rotation for 10min and then centrifuged at 16,000g for 8min at 4°C in
a refrigerated microfuge. The corresponding supernatants were
recovered, and the A260 was measured using a NanoDrop ND‐1000
Spectrophotometer (Thermo Fisher Scientific). About 10 absorption
units of A260 were layered on top of 7%–50% (w/v) sucrose gradients
prepared in 50mM Tris‐acetate, pH 7.5, 50mM NH4Cl, 12mM MgCl2,
1mMDTT. The gradients were centrifuged at 260,110 g (39,000 rpm) in
a Beckman SW41 rotor at 4°C for 2 hr 45min. To dissociate the vacant
80S ribosomes, high‐salt conditions were achieved by adding NaCl to a
final concentration of 0.25M in the gradients. Gradient analysis was
performed with an ISCO UA‐6 system (Isco, Inc. Lincoln, NE) equipped
to continuously monitor the A254.
2.13 | Expression of Bim, Bak, and Bax in Beclin‐1
immunoprecipitated fraction
A volume of the cell lysate (500 µg protein) was mixed with
immunoprecipitation buffer (20mM Tris–HCl pH 7.5, 1% Triton
X‐100, 150mM NaCl, 10% glycerol, 1mM Na3VO4, 50mM NaF,
2mM EDTA, 1mM PMSF, commercial proteases inhibitor cocktail
(P8340, Sigma‐Aldrich), and 2 µg of anti‐Beclin‐1 antibodies (sc‐48341,
Santa Cruz Biotechnology Inc.) at 4°C overnight. Afterward, protein G
Sepharose (35 ll; GE Healthcare) was added, agitated for 3 hr, and the
washed resin was loaded onto a 10% SDS‐PAGE electrophoresis gel. The
expression of Bim, Bak, and Bax was assessed by western‐blot analysis as
described above. The immunoprecipitation using unspecific mouse IgG
(sc‐2025; Santa Cruz Biotechnology) and anti‐Beclin‐1 antibodies were
run in parallel. The expression of Bim, Bak, and Bax has also been
measured in cell lysate (50 µg proteins).
2.14 | Statistical analysis
All results are expressed as the mean ± standard error of the mean of
independent experiments (n =4–10). Data were compared using the
analysis of variance with the least significant difference’s test as post‐
hoc multiple comparison analysis (homogeneity of variances) or Games–
Howell analysis (nonhomogeneity of variances). If Shapiro–Wilks’s test
showed nonnormal distribution of data, nonparametric Kruskal–Wallis
coupled to U Man–Whitney posthoc analysis with Finner’s correction
was done. The level of significance was set at *p≤ 0.05, **p≤ 0.01,
***p ≤0.001. The groups significantly different (p ≤0.05) were indicated
with different letters.
3 | RESULTS
3.1 | Sorafenib administration reduced tumor cell
growth in xenograft mouse model
The administration of sorafenib tosylate (30–100 mg/kg) orally
once daily reduced growth and angiogenesis while promoting
apoptosis in tumors developed by PLC/PRF/5 (Liu et al., 2006) and
patient‐derived cell lines (Huynh et al., 2009) subcutaneously
implanted in severe combined immunodeficient mice. Sorafenib
tosylate (200 mg/kg) was administered to nude mice once daily
when the diameter of the tumors reached 5 mm. The weight of
animals did not change with the treatment (Supporting Informa-
tion Figure S1a). The administration of sorafenib reduced tumor
volume (Figure 1a and Supporting Information Figure S1b)
in parallel to an increase of caspase‐3 activity (Figure 1b),
cleaved PARP (Figure 1c) and autophagic markers (Beclin‐1 and
LC3II/LC3I; Figure 1d) in tissue homogenate from tumors derived
after implantation of HepG2 cells in nude mice. The expression of
p62 in tumors was not reduced in tumors from sorafenib‐treated
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animals (Figure 1d). Sorafenib also reduced the volume of
tumors derived after implantation of Huh7 and Hep3B in nude
mice (Supporting Information Figure S1b). Sorafenib increased
apoptosis (TUNEL staining; Supporting Information Figure S1c)
and reduced cell proliferation (Ki67; Supporting Information
Figure S1d), fibrogenesis (α‐SMA; Supporting Information
Figure S1e), angiogenesis (CD31; Supplementary Figure S1f) and
stemness (CD34; Supporting Information Figure S1g).
3.2 | Sorafenib reduced cell proliferation and
increased apoptosis
Primary human hepatocytes were resistant to the proapoptotic
properties of sorafenib (Figure 2a). However, the administration of
sorafenib (10 µM) increased caspase‐3 in the three HCC cell lines tested
at 24 hr, with HepG2 being more susceptible than p53‐deficient
HCC cell lines (Hep3B and Huh7) to the treatment (Figure 2a).
Differently, sorafenib moderately reduced cell proliferation in primary
hepatocytes, whereas it drastically blocked cell proliferation in HCC cell
lines with a half maximal inhibitory concentration (IC50) close to 10 µM
(Figure 2b; 24 hr).
3.3 | Induction of endoplasmic reticulum
stress by sorafenib
The ER is responsible for the regulation of protein folding and cellular
calcium concentrations through three ER transmembrane proteins:
PERK, ATF6, and IRE1 (Fribley, Zhang, & Kaufman, 2009; Szegezdi,
Logue, Gorman, & Samali, 2006). Shi et al. (2011) have reported that
sorafenib (20 µM) induces ER stress independently of MEK/ERK
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F IGURE 1 Effect of sorafenib on the tumor progression in the xenograft mouse model. HepG2 (10 × 106) were implanted at dorsal level in
athymic mice and treatment was initiated when tumor reached 5mm using oral administration of sorafenib (200mg/kg) or solvent, being killed
when one tumor size reached 15mm of diameter. Sorafenib reduced tumor size (a), and increased caspase‐3 activity (b), cleaved PARP (c), and
autophagy markers (Beclin‐1 and LC3II/LC3I) (d) in tumor homogenates. Protein expression was analyzed by western‐blot. Results are
expressed as mean ± standard error of the mean, and with the blots are representative of 10 independent experiments. *p ≤ 0.05, **p ≤ 0.01 and
***p ≤ 0.001 between control and sorafenib treatment. The groups with different letters (a or b) were significantly different (p ≤ 0.05)
F IGURE 2 Regulation of caspase‐3 activity (a) and cell proliferation (b) by sorafenib in HepG2, Hep3b, Huh7, and human primary
hepatocytes. Caspase‐3 activity was measured by commercial chemiluminescence‐based assay as described in Material and Methods. Cell
proliferation was determined by BrdU incorporation as described in Material and Methods. The variables were evaluated 24 hr after sorafenib
(0, 10 nM, 10 µM, and 100 µM) administration. Results are expressed as mean ± standard error of the mean of 3–5 independent experiments.
*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 between control and sorafenib‐treated cells. The groups with different letters (a, b, or c) were significantly
different (p ≤ 0.05)
through PERK and IRE1 pathways that are related to increased
apoptosis and autophagy markers respectively in HepG2 and
PLC/PRF/5. In agreement with these studies, our data showed that
sorafenib (≥10 µM) not only increased the ratio of Ser51P‐eIF2α/eIF2α
protein expression (Figure 3a) and the protein expression of the
C/EBP homologous protein (GADD153 or CHOP; Figure 3b) at 6 hr,
but also that of IRE1α (Figure 3c), and the mRNA expression of
XBP1s/XBP1 ratio (Supporting Information Figure S2) at 12 hr.
Interestingly, we have observed that sorafenib reduced ATF6 protein
expression (Figure 3d) at the same range of concentration and time
period as increased PERK and IRE1 pathways (Figure 3a and 3c,
respectively).
3.4 | Sorafenib decreased Ser2481P‐mTOR
phosphorylation, impaired initiation of protein
synthesis and increased transient autophagy
The induction of apoptosis by sorafenib has been related to an alteration
of protein translation characterized by a reduction of elF4E phosphoryla-
tion and Mcl‐1 translation, but unassociated with MEK/ERK down-
regulation in HCC cells (Liu et al., 2006). The mTOR integrates nutrient
and mitogen signals to regulate cell growth and cell proliferation.
Different pathways have been shown to regulate mTOR signaling by
antitumoral agents. The ATF4‐mediated increase in the expression of
sestrin‐2 caused by nelfinavir‐ and bortezomib‐induced AMPK activity
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F IGURE 3 Expression of markers from
all three branches of ER stress altered by
sorafenib in HepG2 cells. A kinetic analysis
of the protein expression of Ser51P‐eIF2α/
eIF2α (a), CHOP (b), IRE1α (c) and ATF6 (d)
were determined at different sorafenib
concentrations (0, 10 nM, 10 µM, and
100 µM) by western‐blot analysis as
described in Material and Methods. Results
are expressed as mean ± standard error of
the mean, and with the blots are
representative of five independent
experiments. *p ≤ 0.05, **p ≤ 0.01, and
**p ≤ 0.001 between control and sorafenib
treated cells. The groups with different
letters (a, b, c, d, or e) were significantly
different (p ≤ 0.05). ATF6, activating
transcription factor 6; CHOP, C/EBP
homologous protein; ER, endoplasmic
reticulum
inhibits mTOR and triggers autophagy in breast, ovarian, and cervical
cancer cell lines (Brüning, Rahmeh, & Friese, 2013). Sorafenib promoted
an early perturbation of the mitochondrial function, ATP depletion and
AMPK‐dependent inhibition of the mTORC1 pathway in breast cancer
cells (Fumarola et al., 2013). In addition, the sustained activation of
phosphatidylinositol 3‐Kinase (PI3K)/AKt upregulating mTOR has also
been related to sorafenib resistance in HCC cells (Chen et al., 2011). In
the current study, we observed that sorafenib (10 µM) caused an early
and progressive reduction (3–24hr) of Ser2481P‐mTOR phosphorylation in
HepG2 (Figure 4a), as well as in Hep3B and Huh7 cells (Supporting
Information Figure S3). Sorafenib (10 µM) induced an early upregulation
of Thr308P‐AKt phosphorylation (6–12hr) followed by downregulation of
Thr308P‐Akt and Ser473P‐Akt phosphorylation (24–48 hr; Figure 4b).
Sorafenib also induced a rapid and transient increase of Thr172P‐AMPK
phosphorylation (6–12hr; Figure 4c). Data suggest that mTOR inhibition
may be related to the combined signaling of AKt inhibition and AMPK
activation.
The inhibition of mTOR by sorafenib has a great impact on
protein translation. The polysome profiles in control cells were
obtained by observing free 40S and 60S ribosomal subunits, 80S
ribosomes, and actively translating polysomes. However, sorafenib
(10 µM) resulted in abnormal polysome profiles, with a dramatic
increase of the 80S peak and a reduction of polysomes (Figure 4d).
Salt treatment dissociated most of the 80S peak into free 40S and
60S ribosomal subunits, indicating that the large 80S ribosome
population was mostly nontranslating vacant ribosomes rather than
monosomes engaged with mRNA (Supporting Information Figure S4).
The nutrient deprivation, growth factor withdrawal or hypoxia
are related to autophagy induction (He & Klionsky, 2009). The most
important pathways involved in autophagy modulation are mTORC1
and AMPK (Prieto‐Dominguez et al., 2016). We used the double
fluorescent‐tagged LC3 (pDest‐LC3‐GFP‐mCherry) plasmid to
distinguish autophagosomes from autolysosomes, transmission
electronic microscopy (TEM), and biochemical markers to follow
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F IGURE 4 Kinetic study of the phosphorylation of mTOR (a), AKt (b), AMPK (c), as well as the alteration in the polysome profile (d) in HepG2
cells treated with sorafenib (10 µM). The protein expression was determined by western‐blot. Polysome profiles were generated following the
procedure described in Material and Methods after 12 hr of sorafenib (10 µM) treatment. Results are expressed as mean ± standard error of
the mean, and with the blots are representative of four independent experiments. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 between control and
sorafenib‐treated cells. The groups with different letters (a, b, c, or d) were significantly different (p ≤ 0.05). AMPK, 5′AMP‐activated protein
kinase; mTOR, mammalian target of rapamycin
the induction and progression of autophagy flux. We found that
sorafenib induced autophagolysosome formation in mRFP‐EGFP‐
LC3‐transfected cells (Figure 5a), a fact confirmed by TEM imaging
(Figure 5b). The quantification of the phagolysosomes (black line)
and phagosomes (grey line; Supporting Information Figure S5) and
biochemical markers (p62, Beclin‐1, and LC3II/I) in HepG2 (Figure 5c)
showed that autophagy induced by sorafenib (10 µM) was only
transiently active (6–12 hr).
3.5 | The inhibition of the ER stress and AMPK
downregulated autophagy and increased apoptosis in
sorafenib‐treated HepG2 cells
We have evaluated the specific role of ER stress arms and AMPK on
autophagy and apoptosis using si‐RNA technology and dorsomorphin,
respectively. Data showed that IRE1α and PERK were deeply
involved in sorafenib‐induced autophagy, whereas a minor effect
of ATF6 was also observed (6 hr; Figure 6a). Thus, the reduction
of autophagy by si‐IRE1α and si‐PERK increased sorafenib
(10 µM)‐induced caspase‐3 activity (Figure 6b) and PARP cleavage
(Figure 6c) in HepG2.
Moreover, the AMPK inhibition by dorsomorphin reduced
Thr172P‐AMPK/AMPK, Ser413P‐Foxo3a/Foxo3a, and Beclin‐1 expres-
sion induced by sorafenib (Figure 6d; 12 hr). However, the sustained
reduction of the activating phosphorylation of Thr172P‐AMPK/AMPK
by dorsomorphin was related to a drastic upregulation of Beclin‐1
expression (Figure 6d), and downregulation of caspase‐3 activity
(Figure 6e) and PARP cleavage (Figure 6f) at 24 hr in sorafenib‐
treated HepG2 cells. In addition, the antiapoptotic properties of
autophagy were further confirmed using autophagic inhibitors 3MA
and CQ by the upregulation of sorafenib (10 µM)‐induced caspase‐3
activity (Figure 6g) and PARP cleavage (Figure 6h) in HepG2 (24 hr).
3.6 | Sorafenib regulated the activation of JNK and
Foxo3a, and the expression of proapoptotic, and
antiapoptotic Bcl‐2 family members
The Bcl‐2 family is a well characterized protein family including
antiapoptotic members (Bcl‐2, Mcl‐1, and Bcl‐xL), proapoptotic
effectors (Bax and Bak) and proapoptotic BH3‐only members, which
include the BH3‐only direct activators Bim, Bid, and Puma (Kim et al.,
2006) and the sensitizers/repressors such as Noxa, Bad, Bik, Bmf, and
HRK (Willis et al., 2007). The interactions among them, as well as
with the autophagic component Beclin‐1, result in a potential switch
between autophagic and apoptotic cell death pathways. The
induction of apoptosis by sorafenib has been related to activation
of Bax and Bak, and increased expression of proapoptotic
“BH3‐domain only” PUMA and BIM, as well as decreased protein
levels of the antiapoptotic Mcl‐1 (Fernando et al., 2012). The
expression of Bim, Bak, Bax, tBid, Bcl‐2, Bcl‐xL, Beclin‐1, and Mcl‐1
in sorafenib (10 nM and 10 µM)‐treated HepG2 cells is shown in
Figure 7a and Supporting Information S6a and S6b. The line chart in
Figure 7b shows the profile throughout time in the expression of
mentioned proteins. Our data suggest that sorafenib (10 µM) induced
a rapid drop of Mcl‐1 protein expression, as well as transient and
moderate increase of tBid, BimEL Bcl‐2 and Bcl‐xL (3–6 hr) over-
lapping with the increase of Beclin‐1 (3–12 hr). The expression of
tBid drastically dropped below the control value at 6 hr, and Bcl‐2,
Bcl‐xL and Beclin‐1 expressions were reduced at 12 hr after
sorafenib treatment (Figure 7b). Among the proapoptotic members,
only BimEL showed a sustained increase throughout the kinetic study,
reaching the highest value at 24 hr (Figure 7). Bak also showed a
moderate rise throughout the study, while Bax expression increased
transiently (3–6 hr) returning expression to the control level
(Figure 7).
The activation of JNK has been related either to ER‐related
autophagy (Ogata et al., 2006) or apoptosis (Dhanasekaran & Reddy,
2008) according to different experimental conditions. The stimula-
tion of ER‐induced autophagy by sorafenib showed above was
associated with the transient activation of JNK as measured by Thr183,
Tyr185P-JNK1/2/JNK1/2 ratio (3–12 hr; Figure 7c and 7d). The
inhibition of the Thr183,Tyr185P-JNK1/2/JNK1/2 ratio was assessed
using the specific inhibitor SP600125 (Figure 7d). The treatment
reduced cell proliferation in control and sorafenib‐treated HepG2
cells (33% and 41% at 12 hr, and 53% and 22% at 24 hr, respectively;
Figure 7e). In contrast, SP600125 increased caspase‐3 in control and
sorafenib‐treated HepG2 cells (Figure 7f).
The activation of Foxo and its proapoptotic properties is under
regulation of multiple cell signaling (Farhan et al., 2017). The
inhibitory phosphorylation Thr32P‐Foxo3a was transiently upregu-
lated at 6–12 hr, while dropped afterwards in sorafenib (10 µM)‐
treated HepG2 cells (Figure 7g).
The role of Bim, Bak, and Bax has also been assessed using
si‐RNA technology. The reduction of Bim, but not Bak and Bax, by
si‐RNA recovered caspase‐3 control levels in sorafenib (10 µM)‐
treated HepG2 (Figure 8a; 24 hr). The reduction of apoptosis by
si‐RNA Bim was associated with upregulation of p62 expression and
LC3II/LC3I ratio, but without alteration of Beclin‐1 expression in
sorafenib‐treated HepG2 cells (Figure 8b). The immunoprecipitation
experiments showed that Bim, but not Bak and Bax, was able to bind
Beclin‐1 (Figure 8c).
4 | DISCUSSION
Sorafenib is, to date, the only approved first‐line systemic therapy for
patients in advanced stages of HCC. This chemotherapeutic drug has
demonstrated a moderate but significant increase of mean overall
survival in patients with good liver function based on the results in
SHARP and Asia‐Pacific clinical trials (7.9 to 10.7 months in Llovet
et al., 2008; and from 4.2 to 6.5 months in Cheng et al., 2009;
respectively). Beneficial effects have also been reported in patients
with thyroid cancer, acute myeloid leukemia, advanced renal cell
carcinoma, or prostate cancer (Antar, Kharfan‐Dabaja, Mahfouz, &
Bazarbachi, 2015; Chi et al., 2008; Escudier et al., 2007; Luo et al.,
2014). Although sorafenib has been effective in extending the overall
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F IGURE 5 Evaluation of autophagic flux (a), presence of autophagolysosomes by electronic transmission microscopy (b) and expression of
autophagy markers p62, Beclin‐1, and LC3II/I (c) in HepG2 cells treated with sorafenib (10 nM and 10 µM). The autophagic flux was assessed in
HepG2 transfected with double‐tagged pDest‐LC3‐GFP‐mCherry plasmid, which is a pH‐sensitive sensor to monitor autophagy in live cells
(6 hr). The GFP tag is acid‐sensitive while the mCherry tag is acid‐insensitive. Yellow merge punctate structures indicate autophagosomes which
neutral pH allows both tags emit fluorescent light resulting in a yellow staining. Subsequent fusion of autophagosomes with lysosomes results in
red‐positive acidic vacuoles where the green fluorescence from GFP is lost. Arrows indicate a typical example of colocalized particles of GFP
and mCherry signal, while the arrowhead indicates a typical example of a particle with mCherry signal but without GFP signal due to its
degradation. Sorafenib was used at a concentration of 10 µM, while EBSS was used as positive control treatment and chloroquine (50 µM) was
used to inhibit autophagic flux. The presence of autophagolysosomes in HepG2 cells treated with sorafenib (10 µM) was also detected by
transmission electronic microscopy (12 hr) following the procedure described in Material and Methods. The protein expression of autophagy
markers (p62, Beclin‐1, and LC3 II/I) was assessed at 6, 12 and 24 hr in sorafenib (10 nM and 10 µM)‐treated HepG2 cells by western‐blot
procedure as described in Material and Methods. Results are expressed as mean ± standard error of the mean, and with the blots and images
are representative of four independent experiments. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 between control and sorafenib‐treated cells. The
groups with different letters (a, b, c, or d) were significantly different (p ≤ 0.05) [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 6 Effect of knock‐down of ER stress branches, and inhibition of AMPK and autophagy in sorafenib‐induced autophagy and
apoptosis in HepG2. HepG2 cells were first transfected with IRE1α, PERK, and ATF6 si‐RNA duplexes for 48 hr to assess their role in autophagy
(a) and apoptosis (b,c). The expression of IRE1α, Ser51P‐eIF2α/eIF2α and ATF6 was determined to validate si‐IRE1α, si‐PERK, and si‐ATF6
treatments (a). Afterwards, cells were treated for 6 hr with sorafenib (10 nM and 10 µM) and harvested for analysis. The inhibition of AMPK
was carried out by dorsomorphin (5 µM) with or without coadministration with sorafenib (10 µM) being measured Thr172P‐AMPK/AMPK,
Ser413FOXO3a/FOXO3a, and Beclin‐1 (d) as well as caspase‐3 activity (e) and cleaved PARP (f) at 12 and 24 hr. The inhibition of autophagy by
3‐methyl adenine (3MA; 5 µM) or chloroquine (50 µM) administered 2 hr before sorafenib (10 µM) induced caspase‐3 activity (g) and cleaved
PARP protein expression (h) at 24 hr. Autophagy was biochemically followed by the measurement of p62, Beclin‐1 and LC3II/I protein
expression by western‐blot analysis as described in Material and Methods. Apoptosis was analyzed by caspase‐3 activity and cleaved PARP
protein expression as described in Material and Methods. Results are expressed as mean ± standard error of the mean, and with the blots are
representative of four independent experiments. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 between Control and sorafenib‐treated cells. The groups
with different letters (a, b, c, d, e, or f) were significantly different (p ≤ 0.05). AMPK, 5′AMP‐activated protein kinase; ER, endoplasmic reticulum;
PERK, pancreatic ER kinase (PKR)‐like ER kinase
survival of patients, only a minor percentage of patients (2%)
displayed partial response to therapy based on response evaluation
criteria in solid tumors (RECIST) criteria (Llovet et al., 2008), the low
response rate being mainly attributed to intrinsic resistance of HCC
cells to sorafenib (Villanueva & Llovet, 2012). Several studies have
provided mutational profile and identified an average of 30–40
mutations per tumor; among which 5–8 might be driver mutations, as
well as high‐level amplifications of oncogenes in specific chromosome
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F IGURE 7 Kinetic study of the expression of Bcl‐2 family members and Beclin‐1 (a,b), JNK phosphorylation (c), and its inhibition on JNK
phosphorylation (d), cell proliferation (e) and caspase‐3 (f), as well as Foxo3a phosphorylation (g) in sorafenib‐treated HepG2 cells. The effect of sorafenib
(10 nM and 10µM) on the expression of Bcl‐2 family members and Beclin‐1 were followed at 3, 6, 12, and 24hr by western‐blot analysis. The effect of
sorafenib (10 nM and 10 µM) on the Thr183,Tyr185P-JNK1/2/JNK1/2 and Thr32P‐Foxo3a/Foxo3a protein expression ratio was determined at different time
points according to the experiment (3–48hr). The inhibition of JNK was assessed by the administration of SP600125 (20 µM) added to cell culture 12 hr
before sorafenib (10 µM) treatment. Cell proliferation was determined by BrdU incorporation as described in Material and Methods. Caspase‐3 activity
was measured by commercial chemiluminescence‐based assay as described in Material and Methods. Results are expressed as mean± standard error of
the mean, and with the blots are representative of four independent experiments. *p≤0.05 and **p≤0.01 between control and sorafenib‐treated cells.
The groups with different letters (a, b, c, d, e, or f) were significantly different (p≤0.05). JNK, c‐Jun‐N‐terminal kinase
regions. All influence high resistance and reduced extended survival
rate during sorafenib treatment in HCC (Llovet, Villanueva, Lachen-
mayer, & Finn, 2015).
Sorafenib triggers antiproliferative and antiangiogenic effects
through inhibition of the activity of several tyrosine kinase receptors
including VEGFR‐2/3, PDGFR‐β, Flt3, and c‐Kit, nonreceptor tyrosine
kinase receptors such as Flt3, as well as Raf serine/threonine kinase
(Cervello et al., 2012; Wilhelm et al., 2004). Antiproliferative and
antiangiogenic effects induced by sorafenib, both in vitro and in vivo
conditions, are driven through different mechanisms and promote
apoptosis via both the extrinsic and the intrinsic pathway in HCC
cells (Fernando et al., 2012). The in vivo administration of sorafenib
(200mg/kg) reduced tumor growth characterized by reduction of cell
proliferation (ki67) and promoted apoptosis (caspase‐3, cleaved
PARP, and TUNEL) in tumors developed from subcutaneously HCC
implanted cells in nude mice (Figure 1 and Supporting Information
Figure S1). Sorafenib also increased Beclin‐1 and LC3II/LC3I, but did
not reduce the p62 expression in tissue homogenate, which may
reflect high autophagic turnover in coexistence with apoptotic
processes (Figure 1d). The effectiveness of sorafenib is probably a
result of a balance between targeting cancer cells and the
microenvironment (Llovet et al., 2015). In this sense, it is interesting
to notice that the administration of sorafenib reduced fibrogenesis
(α‐SMA), angiogenesis (CD31), and the presence of hematopoietic
stem cells (CD34) in tumors (Supporting Information Figure S1).
These results, as well as those related to the antiproliferative
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F IGURE 8 Effect of knock‐down of
Bim, Bak, and Bax on caspase‐3 activity (a)
and autophagic markers (p62, Beclin‐1, and
LC3II/I) (b), as well as the binding capacity
of Beclin‐1 to Bim, Bak, and Bax (c) in
sorafenib‐treated HepG2 cells. The
expression of Bim, Bak, and Bax was
determined to validate si‐Bim, si‐Bak, and
si‐Bax treatments (a). The variables were
determined at 24 hr after sorafenib
(10 µM) administration. Caspase‐3
activity was measured by commercial
chemiluminescence‐based assay as
described in Material and Methods. The
protein expression of autophagy markers
and proapoptotic Bcl‐2 family members
was assessed by western‐blot analysis. The
immunoprecipitation procedure of Beclin‐1
is described in Material and Methods. The
immunoprecipitation using unspecific
mouse IgG and anti‐Beclin‐1 antibodies
were run in parallel. The expression of Bim,
Bak, and Bax has also been measured in
the cell lysate. Results are expressed as
mean ± standard error of the mean, and
with the blots are representative of eight
independent experiments. *p ≤ 0.05,
**p ≤ 0.01, and ***p ≤ 0.001 between
control and sorafenib‐treated cells. The
groups with different letters (a, b, c, and d)
were significantly different (p ≤ 0.05)
properties of the drug, are mostly dependent on the inhibition of
tyrosine kinase receptors and the Raf/MEK/ERK.
The mechanism by which sorafenib induces apoptosis is not
fully elucidated, and the effectiveness and adverse events are related
to the dose used. The mean trough sorafenib concentration is
4.3 ± 2.5 mg/L in cancer patients under sorafenib monotherapy with
the recommended dose (400mg, 12 hr), which are increased up to
7.7 ± 3.6 mg/L in patients who experienced grade 3 drug‐related
adverse events (Blanchet et al., 2009). The corresponding therapeutic
concentration of sorafenib used in the study is 10 µM. It has been
associated with the inhibition of phosphorylation of the initiation
factor eIF4E and loss of the antiapoptotic Bcl‐2 family members
Mcl‐1 which appear to occur through a MEK/ERK independent
mechanism in different cancer cell lines treated with sorafenib
(Rahmani, Davis, Bauer, Dent, & Grant, 2005; Yu et al., 2005). Mcl‐1,
an antiapoptotic member of the Bcl‐2 family, has been shown to be
an important factor for apoptosis resistance in HCC (Fleischer et al.,
2006). Sorafenib (10 µM) reduced the level of P‐eIF4E and Mcl‐1 at 2
and 16 hr after treatment in HepG2 and PLC/PRF/5 cells (Liu et al.,
2006). However, we found that there is no temporal relationship
between Mcl‐1 downregulation and induction of apoptosis by
sorafenib in HCC cells. In our conditions, caspase‐3 activity was
significantly increased 24 hr after the administration of sorafenib
(10 µM) in HepG2 cells. HCC cells with mutated p53 (Huh7) and
nonsense p53 mutation (Hep3B) required high sorafenib concentra-
tion (100 µM) to induce caspase‐3 activation (Figure 2a). Data
showed that the antiproliferative and proapoptotic kinetics induced
by the drug were more potent in HCC cell lines than in primary
human hepatocytes (Figure 2). In this sense, primary human
hepatocytes were resistant to the proapoptotic properties of
sorafenib treatment (Figure 2a). This aspect is relevant for the
specificity of sorafenib for liver cancer cells instead of healthy
hepatocytes. We undertook experiments to identify the differential
pattern of miRNA expression upon sorafenib treatment among
primary human hepatocytes and cancer cells.
One well‐characterized function of mTORC1 is to maintain protein
synthesis through phosphorylation of at least two direct targets,
eukaryotic initiation factor (eIF) 4E‐binding proteins (4E‐BPs) and
ribosomal protein S6 kinases (S6Ks) (Hay & Sonenberg, 2004). mTOR
is regulated by different cell signaling involving ER stress, AKt, and
AMPK (Rashid, Yadav, Kim, & Chae, 2015). The induction of PERK
signaling by antitumoral drugs inhibits mTOR and triggers autophagy in
different cancer cell lines (Bruning et al., 2013). Sorafenib (10 µM)
significantly increased PERK‐ and IRE1α‐related signaling at 6 hr in
HepG2 cells (Figure 3). The significant reduction of ATF6 (Figure 3d)
may be related to the alteration of trafficking between the ER and the
Golgi apparatus, as well as the overall secretory pathway induced by
sorafenib (Yi et al., 2012). The activation of PERK and IRE1α signaling
was associated with alteration of Thr172P‐AMPK (Figure 4c) and Ser2481P‐
mTOR (Figure 4a). In addition, the early downregulation of mTOR
activation appeared not to be related to reduced AKt phosphorylation.
In fact, Thr308P‐AKt increased 6–12 hr after sorafenib administration in
HepG2 (Figure 4b). The activation of survival pathways on mTOR
inhibition has been associated with upregulation of IGF‐I receptor in
breast (O'Reilly et al., 2006) and rhabdomyosarcoma (Wan, Harkavy,
Shen, Grohar, & Helman, 2007) cell lines. The inhibition of the mTOR
pathway is in agreement with the drastic alteration of polysome profile
we observed in sorafenib‐treated HepG2 cells. In agreement with
Sauzay et al. (2018), sorafenib induced a blockage of translation at initial
stage (Figure 4d and Supporting Information Figure 4).
The most important pathways involved in autophagy modulation are
mTORC1 and AMPK (Prieto‐Dominguez et al., 2016). The inhibition of
mTOR by sorafenib appeared to be stronger in HepG2 (Figure 4a) than in
Hep3B and Huh7 (Supporting Information Figure S3). However, the
activation of autophagic process using the tandem pDest‐LC3‐GFP‐
mCherry plasmid transfected to sorafenib‐treated cells (Figure 5a), TEM
(Figure 5b) and biochemical markers (Figure 5c) were more closely
correlated to the activation of ER stress (Figure 3) and AMPK
(Figure 4c) than mTOR inhibition (Figure 4a). The respective use of
si-RNA and inhibitory compounds showed that ER stress (Figure 6a) and
AMPK activation (Figure 6d) played an essential role during sorafenib‐
induced autophagy in HepG2. The inhibition of autophagy by si‐IRE1α
and si‐PERK, as well as 3MA, and CQ increased caspase‐3 (Figure 6b and
6g, respectively) and PARP cleavage (Figure 6c and 6h, respectively). It
was also interesting to notice that the downregulation of autophagy by
reduction of Thr172P‐AMPK/AMPK ratio using dorsomorphin observed at
12 hr was followed by a drastic upregulation of Beclin‐1 (Figure 6d) and
reduction of caspase‐3 activity (Figure 6e) and PARP cleavage (Figure 6f)
in sorafenib‐treated HepG2 cells at 24 hr. The experiments confirmed
Thr172P‐AMPK/AMPK ratio was positively correlated to the
Ser413P‐Foxo3a/Foxo3a ratio (Figure 6d). Our results support the survival
properties of autophagy, and it may suggest an autophagic alternative
activation pathway in dorsomorphin and sorafenib cotreated HepG2
cells.
Urano et al. (2000) reported that ER stress and, in particular the IRE1
kinase activity, increases JNK activity. The autophagic process, as
apoptosis, appeared to be tightly regulated by anti‐ and proapoptotic
members of the Bcl‐2 family. The activation of the autophagic process (6–
12hr) by sorafenib was associated with a drastic increase of Beclin‐1
expression, which it was preceded by rapid downregulation of Mcl‐1 and
upregulation of tBid and BimEL, while Bcl‐2 and Bcl‐xL remained at
moderate levels during this period after drug administration (Figure 7a
and 7b, and Supporting Information Figure S6). Interestingly, tBid and
BimEL have been shown to promote autophagy by displacing Beclin‐1
from its interaction with Bcl‐2 (Erlich et al., 2007; Marquez & Xu, 2012).
In fact, Beclin‐1 has been identified as a BH3‐only protein (Maiuri et al.,
2007) that allows its interaction with Bcl2 and its homologue Bcl‐xL
(Oberstein, Jeffrey, & Shi, 2007). The expression of Beclin‐1 (Park et al.,
2009) and Bcl‐2 phosphorylation that disrupts Beclin‐1‐Bcl‐2 complex‐1
(Wei, Pattingre, Sinha, Bassik, & Levine, 2008) have been related to the
activation of JNK1. It was interesting to observe that Thr183,Tyr185P-JNK1/
2/JNK1/2 was induced by sorafenib (10 µM) during the period in which
autophagy was activated (3–12hr; Figure 7c). The inhibition of Thr183,
Tyr185P-JNK1/2/JNK1/2 (Figure 7d) by SP600125 was related to a
reduction in cell proliferation (Figure 7e) that resulted in an increased
apoptosis (Figure 7f), suggesting that JNK played a survival role during
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sorafenib‐induced apoptosis. In addition, a timeframe relationship existed
between JNK and AMPK activation, supporting the existence of a
complex signaling module involving LKB1, AMPK and JNK, in which early
phase of JNK activation was also promoting cell survival by inducing
AMPK activity, whereas the late phase of JNK activation induced
apoptosis (Yun et al., 2009).
The activation of apoptosis by sorafenib was coincident with a
sustained increase in BimEL expression, remaining Bak and Bax at a
moderate expression level (Figure 7a and 7b, and Supporting Information
Figure S6). JNK has also been observed to induce phosphorylation of Bim,
promoting its release from its binding to dynein and myosin V motor
complexes (Lei & Davis, 2003). Sorafenib (10 µM) induced a sustained and
progressive increase of CHOP expression (6–24hr; Figure 3b). The main
effector of PERK‐mediated apoptosis is the proapoptotic transcription
factor CHOP which can be induced by ATF4, ATF6, as well as XBP1s
(Verfaillie, Salazar, Velasco, & Agostinis, 2010). Interestingly, CHOP
suppresses the expression of the antiapoptotic Bcl‐2 (McCullough,
Martindale, Klotz, Aw, & Holbrook, 2001) and promotes the transcription
of the proapoptotic BH3‐only protein Bim (Puthalakath et al., 2007). The
induction of thapsigargin‐induced ER has also been related to a
stabilization of Bim by PP2A‐related dephosphorylation that prevents
its ubiquitination and degradation, as well as by transcriptional regulation
though CHOP‐ATF4 in breast cancer cells (Puthalakath et al., 2007). The
expression of Bim is also under positive transcriptional regulation of
Foxo3a (Nakamura & Sakamoto, 2008) whose activity is regulated by a
plethora of kinases such as GSK3β, MST1, JNK, CS1, AMPK, and AKt
(Farhan et al., 2017). As described above, a positive correlation
appeared between Thr172P‐AMPK/AMPK ratio and related activation
phosphorylation of Ser413P‐Foxo3a/Foxo3a ratio (Figure 6d). In addition,
PI3K/AKt survival signaling increases the inhibitory phosphorylation
Thr32P‐Foxo3a, preventing its nuclear translocation and transcriptional
activity (Brunet et al., 1999). Our study also showed that the expression
of BimEL raised shortly after sorafenib administration which was
maintained at moderate expression levels during autophagic‐related
phase (6–12hr). This expression level might be the result of the
interaction between the upregulation of Thr308P‐AKt (Figure 4b)‐
dependent Thr32P‐Foxo3a (Figure 7g), and Thr172P‐AMPK (Figure 4c)‐
dependent Ser413P‐Foxo3a (Figure 6d) in sorafenib‐treated HepG2.
Additional studies should be undertaken to identify the relevance of
each pathway in the expression of BimEL. The sustained increase of PERK
and CHOP expressions (Figure 3a and 3b, respectively) and reduction of
AKt phosphorylation (24 hr; Figure 4b) supports BimEL upregulation
during sorafenib‐induced apoptotic phase (24 hr) in HepG2. The
administration of Bim si‐RNA, but not Bak or Bax, prevented sorafenib‐
induced caspase‐3 activity in HepG2 cells (Figure 8a). The reduction of
apoptosis by Bim si‐RNA was associated with upregulation of p62
expression and LC3II/LC3I ratio, but without alteration of Beclin‐1
expression in sorafenib‐treated HepG2 cells (Figure 8b). The proapoptotic
BH3‐only members such as BimEL, and others like BNIP3, Bad, Bik, Puma,
and Noxa, induce autophagy by disrupting the Beclin‐1‐Bcl2 complex
(Marquez & Xu, 2012). The immunoprecipitation studies demonstrated
the formation of Beclin‐1 and Bim complex (Figure 8c). In this sense, our
study may also suggest that the absence of Bim by si‐RNA promotes the
induction of early autophagic structures by sorafenib (10 µM) indepen-
dently of Beclin‐1 expression which remain at low level at 24 hr
(Figure 8b).
In conclusion, our study showed that the induction of ER stress by
sorafenib was the driving mechanism involved in the sequential
induction of autophagy and apoptosis in HepG2 cells (Figure 9). The
early sorafenib‐induced ER stress and regulation of JNK and AMPK‐
dependent signaling were related to the induction of survival
autophagic process (3–12 hr). The sustained treatment with sorafe-
nib induced a progressive increase of ER stress and PERK‐CHOP‐
dependent rise of BimEL, which induced the shift from autophagy to
apoptosis (24 hr). However, the kinetic of BimEL expression profile
might also be related to the tight balance between AKt‐ and AMPK‐
related signaling in Foxo3a‐dependent BimEL upregulation.
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